source
- STAT+: AstraZeneca’s experimental COPD treatment posts strong results in late-stage studiesAn experimental COPD drug from AstraZeneca could prove competitive with existing treatments, and have a slice of the market to itself.STAT · 44m ago↗ source
- An administrative gap delays access to new pancreatic cancer treatmentA new wave of illegal fruity vapes, more and more kids on GLP-1s, and other health news from Morning RoundsSTAT · 56m ago↗ source
- Inhibrx targets OX40 agonist-cancer vaccine studies from early next yearInhibrx Biosciences says its latest mid-stage results show the potential of its OX40 agonist in immunogenic cancers — but also its prospects in combination with cancer vaccines in tumors with lower…Endpoints